The inhibitor-sensitive sites of galactosyl ceramide galactosidase by Arora, Ramesh C. et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS 166, 77-83 (1973) 
The Inhibitor-Sensitive Sites of Galactosyl Ceramide Galactosidase’ 
RAMESH C. ARORA,2 YUH-NAN LIN, AND NORMAN S. RADIN 
Mental Health Research Illstitute, University of Michigan, 
Ann Arbor, Michigan 48104 
Received November 17, 1972 
A preparation of galactosyl ceramide galactosidase from rat brain has been tested 
with potential inhibitors which resemble the enzyme’s substrate. The amide made 
from 2-hydroxydodecanoic acid and nL-erythro-3-phenyl-2-amino-1,3-propanediol 
proved to be a fine inhibitor, acting noncompetitively. Removal of any of the three 
hydroxyl groups reduced the effectiveness, as did inversion of the C-3 carbon atom 
or addition of substituents on the benzene ring. iV-Acetyl psychosine was an effective 
inhibitor of the mixed type while the longer homolog, N-decanoyl psychosine, was a 
competitive inhibitor as well as substrate for the enzyme. Lactosyl ceramide, the 
naturally occurring lipid, was a competitive inhibitor of modest efficacy. Galactono- 
la&one was an excellent competitive inhibitor and I\r-(n-hexyl) psychosine R-as an 
active inhibitor of the mixed type. It would appear from the above comparisons that 
the enzyme’s active site binds only galactose-containing or galactose-resembling 
substances. while the secondary effector site binds a variety of substances which 
possess the central nitrogenous core region of cerebroside. 
As part of an attempt to develop specific 
agents which could block single steps in 
myelin metabolism, we have synthesized 
compounds which resemble in structure the 
myelin component, galactosyl ceramide 
(“cerebroside”). The hydrolase which nor- 
mally acts on this lipid, a P-galactosidase, is 
defective in the human genetic disorder, 
Krabbe’s disease, and an inhibitor for this 
enzyme might allow us to generate a model 
disorder in rats which mimics the human 
dystrophy. 
We have already described some synthetic 
substances which are effective inhibitors of 
the galactosidase (1). These compounds had 
a st’ructure similar to that of ceramide (the 
product of galactosidase action) in which the 
2-amino-l, 3-propanediol structure was re- 
tained but the long alkenyl side chain of 
sphingosinc was replaced by a benzene ring. 
The very long nonhydroxy fatt’y acids typical 
1 Supported by USPHS Research Grant NS- 
03192. 
2 Present address: Department of Biochemistry, 
The Chicago Medical School, Chicago, IL 6OG12. 
of brain cerebroside were most’ effectively 
replaced by an abnormally short acid, deca- 
noic or dodecanoic acid. Comparison of 
isomers showed that the most active inhibi- 
tor had the el-ythro configuration chnracteris- 
tic of nat~urally occurring sphingosine, and 
deletion of either of the two hydroxyl groups 
on the lipoidal amine drastically reduced the 
inhibitory effect. Substitutions on the ben- 
zene ring also weakened the effect. Kinetic 
analysis of the inhibition some\vhat unex- 
pectedly showed the inhibition to be non- 
competitive and the implication is therefore 
that the inhibitor acts on a relatively distant 
site rather than at the catalytic site of the 
galactosidasc. 
An amide with an even simpler structure, 
N-decanoyl 2-amino-2-methylpropanol, was 
found to be a fairly good stimulator of the 
galactosidnse (2). It is not known if this sub- 
stance acts at the same site as the inhibitor. 
This paper reports the results of further 
attempts to delineate the sensitive sites on 
the enzyme and to search for compounds 
that might bc more effective inhibitors. 
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MATERIALS AND METHODS 
Preparation of the inhibitors. The aromatic 
amines used have been described before (1). DL-2- 
Hydroxy fatty acids were prepared by hydrolyzing 
the bromoacids with KOH in water-tetrahydro- 
furan and the bromo acids were either prepared 
here3 or purchased. 2-Bromodecanoic acid was 
obtained from K&K Laboratories, Inc., Plainview, 
NY. Bromolauric, myristic, and palmitic acids 
were bought from Aldrich Chemical Co., Inc., 
Milwaukee, WI. Psychosine was prepared by hy- 
drolysis of cerebroside with KOH in water-butanol 
(3, 4). 
The 2-hydroxy fatty acids were converted to 
amides through the following sequence: acetyla- 
tion, reaction with thionyl chloride, reaction with 
the amine, and alkaline methanolysis to remove 
the protective acetate group (1, 5). Some acids 
were acetylated with isopropenyl acetate (B), 
others with a modified version of the Fritz-Schenk 
procedure (7). In the latter, 1 mmole of fatty acid 
was dissolved in 1 ml of the acetic anhydride- 
perchloric acid reagent and, after 10 min, the ester 
was isolated by partition between water and 
chloroform. After several washings with water, 
the chloroform layer yielded the ester. Alkaline 
methanolysis was carried out with 0.07 M NaOH in 
chloroform-methanol 2:l for 1 hr. The amide was 
then recovered by partitioning with 0.2 vol of 
acetic acid-water 1:30, washing the lower layer 
with water, and removing the chloroform. 
The hydroxy acid amides made from n-3-phenyl- 
2-amino-I-propanol, after purification with a silica 
gel column, yielded single spots when examined 
by tlc4 with chloroform-methanol-acetic acid 
88:4:8. However, the amides made from DL- 
erythro-3-phenyl-2-amino-3-propanol and DL- 
erythro-3-phenyl-2-amino-1,3-propanediol yielded 
two, equally intense spots on tic plates. A similar 
phenomenon had been observed earlier with cere- 
brosides made from nn-2-hydroxylignoceric acid, 
in which case we found the faster spot to be the 
unnatural compound, containing the n-hydroxy 
acid (5). A similar relationship has been observed 
with ceramides containing nn-hydroxy acids, the 
slower spot being the natural compound, n-hy- 
3 Arora and Radin, unpublished data. 
4 Abbreviations and nomenclature: tic, thin 
layer chromatography (carried out with silica gel 
PF-254, E?vl Reagent). Sphingosine, as used here, 
is the D-erythro, natural isomer (sphingenine). 
Ceramide is fatty acyl sphingosine, an amide. 
Psychosine is 1-(O-p-galactosyl) sphingosine. 
Cerebroside is galactocerebroside, or galactosyl 
ceramide, or N-acyl psychosine. Cerebrosidase is 
the enzyme which hydrolytically cleaves the galac- 
tose from cerebroside. Solvent mixtures are v/v. 
droxy acid, n-amine (8, 16). However, unlike 
Karlsson and Pascher (S), we found the acetyl 
ester (the intermediate in the synthesis) to give 
only a single spot with cerebrosides, ceramides, 
and the aromatic amides. Possibly their faster 
spot was contaminating free fatty acid. 
In the case of the aromatic amides, it is probable 
that the faster spot consists of the racemic mix- 
ture, n-acid, n-amine and n-acid, n-amine and the 
lower spot is n-acid, L-amine with n-acid, D- 
amine. 
Amides of psychosine were made like those of 
the aromatic amines, except (in the case of the 
acetyl compound) that acetic anhydride was used 
instead of acetyl chloride. In these syntheses the 
nonpolar impurities were removed with a silica 
gel column by elution with chIoroform-methanol 
98:2 and the amides were eluted with chloroform- 
methanol 94:6. The tic with silica gel and chloro- 
form-methanol-water-ammonium hydroxide 48: 
14:l:l revealed a single spot for each compound. 
Labeled N-decanoyl psychosine was made from 
[l-i4C]-decanoic acid and diluted to a specific ac- 
tivity of 1100 cpm/nmole. The purified cerebro- 
side yielded one spot with tic with chloroform- 
methanol-water 24:7:1 and counting of the spot 
and nearby tic regions indicated the radiopurity 
to be at least 94%. N-(n-Hexyl)-0-glucosyl sphin- 
gosine was synthesized as previously described (9) 
and the galactosyl analogue was made similarly. 
Cerebroside galactosidase assays. The previously 
described procedure was used (1). This involved 
use of a partially purified galactosidase prepara- 
tion derived from 3 mg of rat brain, incubation 
with an emulsion of radioactive N-stearoyl psy- 
chosine (3), and determination of the amount of 
galactose released. A typical control incubation 
without enzyme yielded 122 cpm, corresponding to 
0.15yo of the amount of cerebroside in the incuba- 
tion tube. The compound to be tested as an in- 
hibitor was first deposited on the walls of the in- 
cubation tube by evaporation from solvent, gener- 
ally at a level which yielded a concentration of 0.3 
mM. After each run, which included control incu- 
bations without inhibitor, the degree of inhibition 
was calculated from the decrease in the number of 
cpm from the control samples. 
RESULTS 
Inhibition by aromatic %hydrozy acid 
amicles. All the amides of m-erythro-3-phen- 
y1-P-amino-l, 3-propancdiol were found to be 
inhibitory (Table I). While there was little 
difference between compounds of differing 
chain length at 0.3 m&f inhibitor concentra- 
tion, the superiority of the dodecanoyl de- 
rivative was more clearly revealed at the 30 
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TABLE I TABLE II 
INHIBITION OF CEREBROSIDASE BY 2-HYDROXY INHIBITION OF CEREBROSID~~SE BY 2-HYDROXY- 
FATTY ACID ‘AWDES OF PHENYL~MINO- DODECANOTL AMIDES OF VARIOUS AROMATIC 
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PM level. In those cases where the three 
isomers were tested, decreased effectiveness 
was observed. 
The omission of either of the two hydroxyl 
groups on the aromatic amine, or the addi- 
tion of a pal-a substitution on the benzene 
ring lead to reduced inhibitory power (Table 
II). The 3-OH group was not as important 
as the l-OH group in producing inhibition. 
Replacement of the benzene ring by an 
alkvl chain (N-hydroxydodecanoyl D-sphin- 
go&e) almost completely destroyed the ill- 
hibitory effect: 10 % at 0.3 m&f and 3 % at 
30 /.lM. 
These findings agree well with the results 
with nonhydroxy acid amides. Apparently 
the best inhibitor contains an acid of about 
12 carbon atoms, attached to an amine bear- 
ing the 1-hydroxy, 2-amino, 3-hydroxy, 3- 
phenyl sequence. The presence of the DL-~Q-- 
droxyl group on the fatty acid also enhances 
the effect; in the case of the decanoates, the 
unsubstit’uted acid produced 48 % inhibition 
at 0.3 nl~v~ and the 2-hydroxy analogue pro- 
duced 67 % inhibition. 
Nature of the inhibition by the propane&o1 
amide. The most active inhibitor, hydroxy- 
dodecanoyl phenylaminopropanediol, was 
evaluated according to the Lineweaver-Burk 
met.hod and found to be of the noncompet.i- 
tive type (Fig. 1). While this was unexpected 
because of the marked similarity between 
the inhibitor and the product of enzyme 
action, a similar finding had been obtained 
\\it’h t,he analogous compound lacking the 
OH on the acyl chain (1). The Ki cslculat,ed 
for the hydroxy inhibitor was 0.10 m&I, which 
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FIG. 1. Lineweaver-Burk plot of the galacto- 
cerebrosidase activity in a rat brain preparation, 
with and without N-hydroxydodecanoyl DL- 
erythro-3-phenyl-2-amino-1,3-propanediol. The in- 
hibitor (upper curve) was added at 0.3 mM. The 
incubation tubes contained varying amounts of 
labeled stearoyl psychosine (expressed as l/m@ 
emulsified with Tween 20 and iV1yrj 59 in the weight 
ratios 1:20:5. The ordinate is expressed as l/ 
&moles cerebroside hydrolyzed in 3 hr. 
can be compared with the value of 0.40 mM 
previously found with the nonhxdroxy in- 
hibitor. 
Measurement. of the inhibitory effect as a 
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function of concentration of the hydroxy 
acid amide showed that maximal inhibit’ion, 
about 82%, was reached at concentrations 
greater than 0.6 mM (Fig. 2). The lack of a 
discontinuity in the curve (a sudden flatten- 
ing off) indicates that solubility limitation 
was not the cause of the failure t’o attain 
higher levels of inhibition. 
The time course of the inhibited and unin- 
hibited hydrolytic reactions proceeded at a 
constant rate, indicating that no chemical 
reaction occurred between the inhibitor and 
the enzyme. 
Inhibition by N-Acyl Psychosines. All the 
acylated psychosine compounds (which are 
actually galactocerebrosides with abnormally 
short fatty acids) proved to be inhibitory 
(Table III). The decanoyl and probably the 
hydroxydodecanoyl amides were the most 
effective. A kinetic analysis of the effect of 
acetyl psychosine showed (Fig. 3) that it acts 
like a mixed type inhibitor-partially com- 
petitive and partially noncompetitive. The 
double mode of action is reflected in the rela- 
tionship between inhibitor concentration and 
inhibitory action (Fig. 4). Instead of leveling 
off, the curve continues to rise, evidently due 
to increasingly effective competition for the 
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FIG. 2. Relationship between degree of inhibi- 
tion and concentration of N-hydroxydodecanoyl 
DL-erythro-phenylaminopropanediol. 
TABLE III 
INHIBITION OF CEREBROSIDASE BY HOMOLOGS OF 
CEREBROSIDE 
Fatty acid Percentage inhibition 
300 pM 30 WM 
cerebroside cerebroside 
12:o 46 16 
lo:o 60 30 
8:0 61 
6:0 62 20 
2:o 57 13 
2-OH 12:0 66 
2.Br 6:0 66 21 
cerebroside and the diminutive cerebroside. 
Even at the low concentration of 75 PN, the 
acetyl compound produced 31% inhibition. 
Decanoyl psychosine, which resembles the 
natural substrate more closely, was found to 
act as a competitive inhibitor. The Ki for 
this interaction was about 86 PM, which can 
be compared with the K, observed with the 
natural substrate: 22 PM. 
To test the possibility t’hat t’he decanoyl 
psychosine was acting as a substrate, we in- 
cubated the enzyme preparation with the 
radioactive inhibitor under the same assay 
conditions used for our usual substrate, 
stearoyl psychosine. Because of the difference 
in site of label, the incubation mixture had 
to be processed via a column separation (5). 
We found that 41% of the lO:O-cerebroside 
was converted to ceramide and that’ negligi- 
ble free fatty acid was formed. The cont’rol 
incubation without enzyme yielded only 
0.5% conversion (or contamination of the 
ceramide fraction). As our enzyme prepara- 
tion hydrolyzes only about 30% of the 18:0- 
cerebroside, it is evident that the shorter 
chain galactolipid is a better substrate and 
might be more useful in determining cere- 
brosidase activities. 
Inhibition by lactosyl ceramide. When we 
first discovered the presence of an effector 
site on the cerebrosidase molecule, sensitive 
to noncompetitive inhibitors, we suggested 
that a naturally occurring ceramide deriva- 
t’ive acts normally at that position, to controi 
the enzyme’s activity (1). One candidate for 
this role is galactosyl glucosyl ceramide, 
an intermediate in ganglioside metabolism, 
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FIG. 3. Inhibitory effect of N-acetyl psychosine 
on galactocerebroside hydrolase. Units as in Fig. 
1. The upper curve was derived from incubations 
containing 0.3 mM inhibitor. 
INHIBITOR CONCENTRATION (Ix 10-4M) 
FIG. 4. Relationship between degree of inhibi- 
tion and concentration of N-acetyl psychosine. 
which occurs in Cssues at low levels. We had 
found the natural compound (prepared by 
partial hydrolysis of gangliosides) to be a 
fnirly good inhibitor (10). A test with N- 
stearoyl 0-lactosyl m-erythw-sphingosine 
(Miles Laboratories, Kankakee, IL) resulted 
in only 27 % inhibition at 0.3 PM. However, 
it is possible that only the n-isomer is the 
active form. A kinetic evaluation of the effect 
showed the m-compound to be a competitive 
inhibitor with a Kc of about 0.S mar. Evi- 
dently the galactosyl moiety of this sub- 
stance brings it to the active site of the en- 
zyme, and it does not fit the proposed role of 
effector substance. However, there is the 
possibility that the high levels of lactosyl 
ccramide seen in certain disorders, as in lac- 
tosyl ceramidosis (ll), could decrease cerr- 
brosidase activity through its attraction to 
the catalytic site. 
This lipid has been found not to inhibit the 
intestinal glucosidase that acts on glucosyl 
ceramidc (12). 
Other inhibitors. Aldonolactones corre- 
sponding to specific glycosides act as com- 
petitive inhibitors of the corresponding gly- 
cosidases (13, 14). Galactonolactone had 
previously been shown to inhibit cerebro- 
sidase as well, and gluconolactone was inef- 
fective (10). WC made a more detailed study, 
using gamma-galactonolactone equilibrated 
to a mixture of isomers, and found that it 
acts as a competitive inhibitor, the Ki being 
about 35 PN (Fig. 5). 
It seemed possible that the lactone might 
combine chemically with the enzyme, possi- 
bly forming an amide or ester linkage with an 
amine or hydroxyl group near the active site. 
However the time course of the inhibitory 
effect was found to be linear over 3 hr, the 
first time point being measured at 30 min. 
Thus it would appear that the lactone simply 
binds through nonchemical forces at the 
galactose-binding region. 
It. is of interest that galactonic acid is a 
normal metabolic product formed from ga- 
lactose (15). While the free acid may not be 
an inhibitor for galactosidases, it’ may be 
converted to the lactone in lysosomes if there 
is a region of low pH in these particles. 
We also tested some compounds relat,ed to 
the antibiotic, chloromycetin. These were 
the amides of dichloroacetic acid and p-sub- 
stit,uted derivatives of 3-phmyl-2-amino- 
1,3-propanediol. The thiomethyl ether of the 
m-thyeo compound, the methyl sulfone of the 
m-erythro compound, and the wbutyl sul- 
fone of the m-three compound all proved to 
be almost inactive at’ 0.3 111~. 
The reduced, short-chain cerebrosides were 
rather inhibit,ory. At 0.3 mai, N-hexyl glu- 
cosyl sphingosine caused about 36% inhibi- 
tion and N-hexyl galactosyl sphingosine 
caused about, GS % inhibition. When evalu- 
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FIG. 5. Lineweaver-Burk plot of enzyme ac- 
tivity vs concentration of substrate. Upper curve, 
obtained with 0.5 mM galactonolactone. Units as 
in Fig. 1. 
ated by the Lineweaver-Burk plot, the glu- 
cosyl compound proved to be a noncompeti- 
tive inhibitor with Ki = 0.30 mM, while the 
galactosyl compound proved to be a mixed 
type inhibitor with Ki = 0.15 mM. When 
tested with the spleen enzyme which hy- 
drolyzes glucosyl ceramide, the glucosyl com- 
pound acted as a highly active competitive 
inhibitor with Ki = 0.33 /ZM (9). Galactosyl 
sphingosine, without an alkyl group, pro- 
duced only 13 % inhibition at 0.3 mM. 
DISCUSSION 
It appears from this and our previous 
study (1) that rat brain cerebroside galac- 
tosidase possesses two sites which can bind 
interfering substances. Some inhibitors bind 
exclusively to the secondary, noncompetive 
site (the aromat’ic amides resembling cera- 
mide and the N-alkyi glucosyl sphingosine), 
while others bind to the secondary and cata- 
lytic sites (acetyl psychosine and N-hexyl 
psychosine). Only the compound most 
closely resembling galactose, galactonolac- 
tone, and the galactoside with the least 
lipoidal aglycone, lactosyl ceramide, binds 
solely to the catalytic site. 
Judging by the above comparisons, it 
would appear that the catalytic site binds 
only galactose-containing or galactose-re- 
sembling compounds. Evidently the design 
of better inhibitors for the active site should 
aim at glycosides with lipoidal aglycones 
containing galactose or a closely relat’ed 
sugar. However such compounds, such as our 
decanoyl psychosine, run the risk of being 
substrates for the enzyme. 
Perhaps a better approach would be the 
synthesis of substances which bind to the 
secondary enzyme site (or sites). It is clear 
that this enzyme region has a strong influ- 
ence on the catalytic efficiency of the cer- 
ebrosidase. 
The high specificity of the secondary bind- 
ing site is striking. It is sensitive to the op- 
tical configuration of the carbon atom bear- 
ing the amide group, and to the presence of 
three different hydroxyl groups, as well as 
to the presence of substituents on the ben- 
zene ring. The best effects are obtained with 
compounds which closely resemble the polar 
segment of hydroxy ceramide. An explana- 
tion for this phenomenon can be based on 
current genetic theory of protein evoIution 
(17). Early in animal history there may have 
been a genetic modification which produced 
a partial duplication of the gene coding for 
cerebrosidase. The new gene then produced 
an elongated molecuIe of eerebrosidase con- 
taining a partial replication of the amino 
acid sequence containing the active site. 
Subsequent mutations may have then modi- 
fied the second active site to its present 
state: no longer catalytically active but still 
able to bind substances resembling t)he nat- 
ural substrate. Several examples of proteins 
containing partial or complete duplication 
are now known (17). 
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